Items where authors include "Allsup, D."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Naylor-Adamson, L., Price, T.W., Booth, Z. et al. (14 more authors) (2025) PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation. Journal of Materials Chemistry B, 13 (3). pp. 1052-1063. ISSN 2050-750X

Gil, H.M., Booth, Z., Price, T.W. et al. (13 more authors) (2024) Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small, 20 (12). 2304881. ISSN 1613-6810

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Hillmen, P., Pitchford, A., Bloor, A. et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Johnson, B., Doak, R., Allsup, D. et al. (15 more authors) (2018) A comprehensive targeted next-generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia. Research and Practice in Thrombosis and Haemostasis, 2 (4). pp. 640-652. ISSN 2475-0379

Johnson, B., Lowe, G.C., Futterer, J. et al. (31 more authors) (2016) Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica. ISSN 0390-6078

Proceedings Paper

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.